Impli’s Solution
“In implantables, real-time hormone monitoring and sensing with aptamer-based sensors is a very new area – there are very few research papers and very few people working on it, but it’s a $10 billion global market, so there are lots of people who are interested in solving this problem and giving would-be parents the very best chance to start a family. Instead of trying to do it via general solutions, such as apps and basal temperature, we’re delivering a much more natural and precise interface to real-time hormone data.”- Anna-Luisa Schaffgotsch, Impli CEO and founder
Impli’s pioneering innovation – the first real-time hormone monitoring device for IVF – aims to make fertility treatment safer, more accessible, and more successful. By delivering real-time insights into the patient’s hormonal profile, the implantable technology can assist fertility specialists in selecting the best treatment and optimizing medication dosages and timing.
With the ability to identify potential issues such as Ovarian Hyperstimulation Syndrome (OHSS), Impli’s device also enables management and key interventions to prevent complications – helping doctors to make the informed decisions and personalized, predictive care that can maximize the chances of a successful pregnancy.
Impli has recently been featured in the Octopus Ventures Future of Fertility Report as a “Company to Watch” in the fertility tech space.
How Femovate Helps
Impli was awarded sponsorship through Guidea’s Femovate program for ‘23-’24.
As part of the Femovate sponsorship, designers at Guidea will work closely with the Impli team to create and validate the initial digital customer experience to accompany the medical device.
For more information about Impli, visit https://www.impli.org/ and follow them on LinkedIn
For more information on Femovate visit www.femovate.com and follow us on LinkedIn
For interviews please contact Theresa Neil
